You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 6, June 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

G. M. Fenichel, J. R. Mendell, R. T. Moxley 3rd, R. C. Griggs, M. H. Brooke, J. P. Miller, A. Pestronk, J. Robison, W. King, L. Signore and al. et
Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212.

We previously reported the results of a randomized, double-blind 6-month trial of prednisone therapy in which 102 boys aged 5 to 15 years with Duchenne muscular dystrophy received daily doses of 1.5 and 0.75 mg/kg per day and were compared with those receiving placebo. The strength and function in both prednisone-treated groups improved equally and were significantly better than in the placebo group. To compare alternate-day and daily dosing of prednisone with respect to benefits and adverse side effects, the placebo group was started on alternate-day prednisone therapy, and the treatment group regimens were changed to equivalent doses of alternate-day prednisone without breaking the double-blind nature. At the end of 6 months, the group that was changed from daily to alternate-day therapy had declined in strength back to levels observed 12 months previously, at the start of daily therapy. The group in which alternate-day therapy was started showed a significant improvement in strength at 3 months, similar in magnitude to the response of boys treated with daily therapy. However, their strength declined significantly in the subsequent 3 months compared with boys who received daily therapy. The frequency of side effects was not significantly different for alternate-day therapy compared with daily therapy. We conclude that alternate-day prednisone therapy effectively increases strength but does not sustain the improvement to the same extent as daily therapy or mitigate side effects.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King et al.
Neurology 2007;68:1607-1613.
ABSTRACT | FULL TEXT  

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
Bonifati et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:1177-1179.
ABSTRACT | FULL TEXT  

Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Moxley et al.
Neurology 2005;64:13-20.
ABSTRACT | FULL TEXT  

Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy: A Randomized Controlled Trial
Beenakker et al.
Arch Neurol 2005;62:128-132.
ABSTRACT | FULL TEXT  

Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal
Wong and Christopher
J Child Neurol 2002;17:183-190.
ABSTRACT  

Prednisone Therapy in Becker's Muscular Dystrophy
Johnsen and Clinic
J Child Neurol 2001;16:870-871.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.